SCHEDULE: Vanguard Group Adjusts Aldeyra Therapeutics Reporting

The Vanguard Group reports 0% beneficial ownership in Aldeyra Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Aldeyra Therapeutics Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Aldeyra Therapeutics Inc. securities.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. It clarifies The Vanguard Group's reporting structure but provides no new information regarding Aldeyra Therapeutics' operational or financial performance.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

The Vanguard Group's subsidiaries or business divisions will now report beneficial ownership separately, pursuing the same investment strategies as previously.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this administrative filing reflects a common practice among large asset managers to adjust their reporting structures for beneficial ownership, often driven by internal reorganizations or regulatory interpretations. It does not inherently signal a change in investment thesis for Aldeyra Therapeutics by Vanguard's broader investment complex, but rather a shift in how those holdings are disclosed.

Stakeholder Impact

• Shareholders of Aldeyra Therapeutics Inc. may observe a change in the reported institutional ownership by The Vanguard Group, though the underlying holdings by Vanguard's subsidiaries may persist. This is primarily a reporting change.

Next Steps

• Vanguard Group's subsidiaries or business divisions will report beneficial ownership separately.

Key Dates

Keywords

Aldeyra Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Investment Management, Common Stock